1. Home
  2. STTK vs QMCO Comparison

STTK vs QMCO Comparison

Compare STTK & QMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • QMCO
  • Stock Information
  • Founded
  • STTK 2016
  • QMCO 1980
  • Country
  • STTK United States
  • QMCO United States
  • Employees
  • STTK N/A
  • QMCO N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • QMCO Electronic Components
  • Sector
  • STTK Health Care
  • QMCO Technology
  • Exchange
  • STTK Nasdaq
  • QMCO Nasdaq
  • Market Cap
  • STTK 83.8M
  • QMCO 98.8M
  • IPO Year
  • STTK 2020
  • QMCO N/A
  • Fundamental
  • Price
  • STTK $1.92
  • QMCO $7.36
  • Analyst Decision
  • STTK Hold
  • QMCO Hold
  • Analyst Count
  • STTK 6
  • QMCO 2
  • Target Price
  • STTK $2.67
  • QMCO $19.00
  • AVG Volume (30 Days)
  • STTK 1.6M
  • QMCO 636.7K
  • Earning Date
  • STTK 08-14-2025
  • QMCO 09-10-2025
  • Dividend Yield
  • STTK N/A
  • QMCO N/A
  • EPS Growth
  • STTK N/A
  • QMCO N/A
  • EPS
  • STTK N/A
  • QMCO N/A
  • Revenue
  • STTK $2,997,000.00
  • QMCO $266,079,000.00
  • Revenue This Year
  • STTK N/A
  • QMCO $7.49
  • Revenue Next Year
  • STTK N/A
  • QMCO $3.22
  • P/E Ratio
  • STTK N/A
  • QMCO N/A
  • Revenue Growth
  • STTK N/A
  • QMCO N/A
  • 52 Week Low
  • STTK $0.69
  • QMCO $2.88
  • 52 Week High
  • STTK $3.95
  • QMCO $90.64
  • Technical
  • Relative Strength Index (RSI)
  • STTK 72.13
  • QMCO 46.24
  • Support Level
  • STTK $1.68
  • QMCO $7.07
  • Resistance Level
  • STTK $2.04
  • QMCO $8.62
  • Average True Range (ATR)
  • STTK 0.19
  • QMCO 0.42
  • MACD
  • STTK 0.09
  • QMCO 0.07
  • Stochastic Oscillator
  • STTK 89.29
  • QMCO 21.74

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About QMCO Quantum Corporation

Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).

Share on Social Networks: